Literature DB >> 30975619

Parkinsonism in PGK1 deficiency implicates the glycolytic pathway in nigrostriatal dysfunction.

Hugo Morales-Briceño1, Ainhi D Ha2, Kevin London3, David Farlow4, Florence C F Chang5, Victor S C Fung6.   

Abstract

BACKGROUND: Phosphoglycerate kinase-1 deficiency is caused by X-linked recessive mutations in PGK-1 and associated with haemolytic anaemia, rhabdomyolysis, myopathy and nervous system involvement. Some cases have been rarely associated with juvenile Parkinsonism however the causal relationship between PGK1 deficiency and nigrostriatal dysfunction causing Parkinsonism has not been determined. OBJECTIVE AND METHODS: To investigate the nigrostriatal system using 99mTc-TRODAT-1 SPECT binding and report the phenotype of three affected males with early onset levodopa responsive Parkinsonism harbouring the c.491 A > T/p.D164V pathogenic variant.
RESULTS: All patients initially presented with infantile-onset encephalopathic and stroke-like episodes, haemolytic anaemia and epilepsy. Two patients had an early-onset and one juvenile-onset levodopa responsive Parkinsonism with motor fluctuations. 99mTc-TRODAT-1 SPECT showed severe bilateral reduced putaminal uptake in the three patients. None of the patients had structural lesions that could explain either pre- or postsynaptic dopaminergic dysfunction.
CONCLUSION: These cases provide strong evidence of a causal relationship between PGK1 deficiency and nigrostriatal pathology causing Parkinsonism. These findings have potential implications for our understanding of the pathophysiology of nigrostriatal degeneration in sporadic PD.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Glycolysis; Juvenile parkinsonism; Pathophysiology; Phosphoglycerate kinase deficiency

Mesh:

Substances:

Year:  2019        PMID: 30975619     DOI: 10.1016/j.parkreldis.2019.04.004

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  6 in total

Review 1.  PGK1-mediated cancer progression and drug resistance.

Authors:  Yu He; Yang Luo; Dan Zhang; Xixi Wang; Peng Zhang; Haocheng Li; Samina Ejaz; Shufang Liang
Journal:  Am J Cancer Res       Date:  2019-11-01       Impact factor: 6.166

Review 2.  Glycolysis: The Next Big Breakthrough in Parkinson's Disease.

Authors:  Unaiza Naeem; Abdul Rehman Arshad; Areesha Jawed; Farea Eqbal; Laiba Imran; Zayeema Khan; Farhat Ijaz
Journal:  Neurotox Res       Date:  2022-09-24       Impact factor: 3.978

3.  Cerebroventricular Injection of Pgk1 Attenuates MPTP-Induced Neuronal Toxicity in Dopaminergic Cells in Zebrafish Brain in a Glycolysis-Independent Manner.

Authors:  Cheng-Yung Lin; Hsiang-Chien Tseng; Yu-Rong Chu; Chia-Lun Wu; Po-Hsiang Zhang; Huai-Jen Tsai
Journal:  Int J Mol Sci       Date:  2022-04-08       Impact factor: 6.208

4.  Activation of PGK1 under hypoxic conditions promotes glycolysis and increases stem cell‑like properties and the epithelial‑mesenchymal transition in oral squamous cell carcinoma cells via the AKT signalling pathway.

Authors:  Yadong Zhang; Hongshi Cai; Yan Liao; Yue Zhu; Fang Wang; Jinsong Hou
Journal:  Int J Oncol       Date:  2020-06-16       Impact factor: 5.650

5.  Single-cell transcriptomics of human iPSC differentiation dynamics reveal a core molecular network of Parkinson's disease.

Authors:  Gabriela Novak; Dimitrios Kyriakis; Kamil Grzyb; Michela Bernini; Sophie Rodius; Gunnar Dittmar; Steven Finkbeiner; Alexander Skupin
Journal:  Commun Biol       Date:  2022-01-13

6.  Parkinson's disease protein PARK7 prevents metabolite and protein damage caused by a glycolytic metabolite.

Authors:  Isaac P Heremans; Francesco Caligiore; Isabelle Gerin; Marina Bury; Marilena Lutz; Julie Graff; Vincent Stroobant; Didier Vertommen; Aurelio A Teleman; Emile Van Schaftingen; Guido T Bommer
Journal:  Proc Natl Acad Sci U S A       Date:  2022-01-25       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.